In the European Union, the
Committee for Medicinal Products for Human Use (CHMP) has recommended 2 novel
cancer drugs for approval — trastuzumab emtansine (Kadcyla, Roche) for the treatment of
metastatic breast cancer, and radium-223 chloride (Xofigo, Bayer) for the treatment of
castration-resistant prostate cancer. Both have been shown to prolong survival.
